Boston Scientific and Graco Hit 52-Week Lows on Growth and Earnings Concerns

Key Facts

Amid shifting dynamics in the healthcare and industrial sectors, major players are facing sharp selling pressure that has pushed their valuations to new lows. Boston Scientific stock hit a 52-week low of $47.16, marking a significant 51% decline over the past year as analysts raised concerns regarding a growth slowdown for its Watchman device. Similarly, Graco Inc shares dropped to $73.48 following Q1 2026 financial results that failed to meet Wall Street's revenue and earnings expectations.

This downturn occurs as investors weigh competition in the medical device space, where peer Abbott Laboratories recently reported robust growth in its cardiovascular segment, intensifying pressure on Boston Scientific's market share. Despite Graco announcing a $447 million acquisition of Valco Melton to bolster its portfolio, broader industrial demand remains tepid. Per market data, Graco's current price action reflects a cautious outlook compared to historical sector multiples, even as the company attempts to pivot through strategic M&A.

Future catalysts include upcoming macroeconomic data and the OPEC meeting on June 7, 2026, which may influence industrial production costs. Investors will also be looking for any management commentary regarding the stabilization of Watchman device sales to determine if a bottom has been reached.